Fulcrum Therapeutics Inc Q2 2026 Earnings: Beat on EPS
Fulcrum Therapeutics (FULC) beat Q2 2026 EPS estimates with -$0.25 vs -$0.30 expected, delivering a 17.79% positive surprise on April 27, 2026 earnings report.
Fulcrum Therapeutics (FULC) beat Q2 2026 EPS estimates with -$0.25 vs -$0.30 expected, delivering a 17.79% positive surprise on April 27, 2026 earnings report.
Kilroy Realty Corp beat Q2 2026 EPS estimates by 161.57%, reporting $0.91 vs $0.35 expected, while revenue of $270.05M slightly…
Easterly Government Properties (DEA) crushed Q2 2026 EPS estimates with $0.77 vs $0.09 expected, delivering a 747.08% surprise on revenue…
COPT Defense Properties beat Q2 2026 EPS estimates by 107.02%, reporting $0.69 vs $0.33 expected, while revenue of $200.64M topped…
Commercial BancGroup Inc beat Q2 2026 EPS estimates with $0.73 vs $0.71 expected (3.25% surprise) but missed revenue targets at…
MX reports Q1 2026 earnings April 28 with analysts expecting -$0.23 EPS and $50M revenue. Key focus on path to…
Trane Technologies reports Q1 2026 earnings on April 28. Investors will focus on segment performance, margins, and guidance amid evolving…
Visa reports Q2 2026 earnings April 28 with EPS estimate of $3.16 and revenue forecast of $10.96B. Key focus on…
Weekly screener identifies 12 large-cap stocks offering dividend yields above 3%, led by Pfizer at 6.38% and Verizon at 5.96%…
SPY gained 0.77% as tech stocks surged 2.83%, driving QQQ up 1.91% while DIA declined on mixed sector performance and…